Building climate-sensitive nutrition programmes

The food system and climate are closely interconnected. Although most research has focused on the need to adopt a plant-based diet to help mitigate climate change, there is also an urgent need to examine the effects of climate change on food systems to adapt to climate change. A systems approach can help identify the pathways through which climate influences food systems, thereby ensuring that programmes combating malnutrition take climate into account. Although little is known about how climate considerations are currently incorporated into nutrition programming, climate information services have the potential to help target the delivery of interventions for at-risk populations and reduce climate-related disruption during their implementation. To ensure climate services provide timely information relevant to nutrition programmes, it is important to fill gaps in our knowledge about the influence of climate variability on food supply chains. A proposed roadmap for developing climate-sensitive nutrition programmes recommends: (i) research aimed at achieving a better understanding of the pathways through which climate influences diet and nutrition, including any time lags; (ii) the identification of entry points for climate information into the decision-making process for nutrition programme delivery; and (iii) capacity-building and training programmes to better equip public health practitioners with the knowledge, confidence and motivation to incorporate climate resilience into nutrition programmes. With sustained investment in capacity-building, data collection and analysis, climate information services can be developed to provide the data, analyses and forecasts needed to ensure nutrition programmes target their interventions where and when they are most needed

On the Qubit Routing Problem

We introduce a new architecture-agnostic methodology for mapping abstract quantum circuits to realistic quantum computing devices with restricted qubit connectivity, as implemented by Cambridge Quantum Computing\u27s t|ket> compiler. We present empirical results showing the effectiveness of this method in terms of reducing two-qubit gate depth and two-qubit gate count, compared to other implementations

t|ket> : A retargetable compiler for NISQ devices

We present t|ket>, a quantum software development platform produced by Cambridge Quantum Computing Ltd. The heart of t|ket> is a language-agnostic optimising compiler designed to generate code for a variety of NISQ devices, which has several features designed to minimise the influence of device error. The compiler has been extensively benchmarked and outperforms most competitors in terms of circuit optimisation and qubit routing

Phase gadget synthesis for shallow circuits

We give an overview of the circuit optimisation methods used by tket, a compiler system for quantum software developed by Cambridge Quantum Computing Ltd. We focus on a novel technique based around phase gadgets, a family of multi-qubit quantum operations which occur naturally in a wide range of quantum circuits of practical interest. The phase gadgets have a simple presentation in the ZX-calculus, which makes it easy to reason about them. Taking advantage of this, we present an efficient method to translate the phase gadgets back to CNOT gates and single qubit operations suitable for execution on a quantum computer with significant reductions in gate count and circuit depth. We demonstrate the effectiveness of these methods on a quantum chemistry benchmarking set based on variational circuits for ground state estimation of small molecules

Parvovirus 4 Infection and Clinical Outcome in High-Risk Populations

Parvovirus 4 (PARV4) is a DNA virus frequently associated with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections, but its clinical significance is unknown. We studied the prevalence of PARV4 antibodies in 2 cohorts of HIV- and HCV-infected individuals (n=469) and the correlations with disease status. We found that PARV4 infection frequently occurred in individuals exposed to bloodborne viruses (95% in HCV-HIV coinfected intravenous drug users [IDUs]). There were no correlations between PARV4 serostatus and HCV outcomes. There was, however, a significant association with early HIV-related symptoms, although because this was tightly linked to both HCV status and clinical group (IDU), the specific role of PARV4 is not yet clea

First Results from Sentinel-1A InSAR over Australia: Application to the Perth Basin

Past ground-based geodetic measurements in the Perth Basin, Australia, record small-magnitude subsidence (up to 7 mm/y), but are limited to discrete points or traverses across parts of the metropolitan area. Here, we investigate deformation over a much larger region by performing the first application of Sentinel-1A InSAR data to Australia. The duration of the study is short (0.7 y), as dictated by the availability of Sentinel-1A data. Despite this limited observation period, verification of Sentinel-1A with continuous GPS and independent TerraSAR-X provides new insights into the deformation field of the Perth Basin. The displacements recorded by each satellite are in agreement, identifying broad (>5 km wide) areas of subsidence at rates up to 15 mm/y. Subsidence at rates greater than 20 mm/y over smaller regions ( 2 km wide) is coincident with wetland areas, where displacements are temporally correlated with changes in groundwater levels in the unconfined aquifer. Longer InSAR time series are required to determine whether these measured displacements are representative of long-term deformation or (more likely) seasonal variations. However, the agreement between datasets demonstrates the ability of Sentinel-1A to detect small-magnitude deformation over different spatial scales (from 2 km–10 s of km) in the Perth Basin. We suggest that, even over short time periods, these data are useful as a reconnaissance tool to identify regions for subsequent targeted studies, particularly given the large swath size of radar acquisitions, which facilitates analysis of a broader portion of the deformation field than ground-based methods or single scenes of TerraSAR-X

Parvovirus 4 Infection and Clinical Outcome in High-Risk Populations

Parvovirus 4 (PARV4) is a DNA virus frequently associated with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections, but its clinical significance is unknown. We studied the prevalence of PARV4 antibodies in 2 cohorts of HIV- and HCV-infected individuals (n = 469) and the correlations with disease status. We found that PARV4 infection frequently occurred in individuals exposed to bloodborne viruses (95% in HCV-HIV coinfected intravenous drug users [IDUs]). There were no correlations between PARV4 serostatus and HCV outcomes. There was, however, a significant association with early HIV-related symptoms, although because this was tightly linked to both HCV status and clinical group (IDU), the specific role of PARV4 is not yet clear

Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals

Little is known about engagement and retention in care of people diagnosed with chronic hepatitis C (HCV) in England. Establishing a cascade of care informs targeted interventions for improving case-finding, referral, treatment uptake and retention in care. Using data from the Sentinel Surveillance of Blood Borne Virus testing (SSBBV) between 2005-2014 we investigate the continuum of care of those tested for HCV in England. Persons ≥1 years old, with an anti-HCV test and subsequent RNA tests between 2005-2014 reported to SSBBV were collated. We describe the cascade of care, as the patient pathway from a diagnostic test, referral into care, treatment, and patient outcomes. Between 2005-2014, 2,390,507 samples were tested for anti-HCV, corresponding to 1,766,515 persons. 53,038 persons (35,190 men and 17,165 women) anti-HCV positive were newly reported to SSBBV. An RNA test, was conducted on 77.0% persons anti-HCV positive, 72.3% of whom were viraemic (RNA positive) during this time period, 21.4% had evidence of treatment, and 3130 49.5% had evidence of a sustained virological response (SVR). In multivariable models confirmation of viraemia by RNA test varied by age and region/test setting; evidence of treatment varied by age, year of test and region/test setting; and SVR varied by age, year of test and region/setting of test. In conclusion, Our findings provide HCV cascade of care estimates prior to the introduction of direct acting antivirals. These findings provide important baseline cascade estimates to benchmark progress towards elimination of HCV as a major public health threat